Augusta Health now offers the Abbott Volt Pulsed Field Ablation System as a safer option for treating AFib patients.

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Sacubitril/valsartan (Entresto) didn't appear to help patients with advanced heart failure in the LIFE trial when compared with an angiotensin receptor blocker alone. The combination agent failed to ...

Adolescents and young adults with advanced heart disease are at high risk of dying in the hospital, often require invasive treatment and experience significant symptoms that impact their quality of ...

Among patients with advanced heart failure and reduced ejection fraction, all-cause and cardiovascular deaths have declined over two decades, but uptake of advanced therapies remains low.

A team led by researchers at UNC-Chapel Hill have developed an innovative computer model of blood flow in the human heart that promises to transform how we understand, diagnose, and treat heart ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. A heart failure diagnosis can be frightening for many ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Updated | Heart disease, the leading cause of death in the U.S., kills ...

Liz covers cardiovascular and metabolic disease, asking why we’re not doing better or even losing ground against the world’s leading killer. Send tips on Signal at LizC.22. By its name and nature, ...

Many adolescent and young adults with advanced heart disease want to be actively involved in decisions about their care, a new survey shows. But often the parents of these patients prefer to face ...

Your heart pumps blood around your body to supply all of your organs with oxygen. When it doesn’t work the way it should anymore, you have what’s known as heart failure. Your ticker may not be strong ...